|
|
|
|
Call Us at 1-800-766-0884
|
|
|
Studies: Abstracts and Presentations
Over 400 published studies support the basic science behind testing pain fibers. Recent studies have shown the Neural-Scan has over 95% sensitivity in the 98% of pain patient who have no muscle weakness. Compared to EMG with only 29% sensitivity in these patients.
Early on it was discovered that different types of nerves respond to specific frequencies. But until the Neural-Scan pain fiber diagnosis was no better than EMG’s 29%. The Neural-Scan works because it is the only device measuring voltage, the component of the electrical signal actually causing the nerve to fire an impulse.
Previously researchers compared current output with nerve firing. They did not realize that current output shifts with the skin’s constantly changing impedance. This shifting is one of the measurements in the well known polygraph lie detector test. Even though in 1952 voltage-gated sodium and potassium channels were discovery by Hodgkins and Huxley, who won the Nobel Prize, not until the Neural-Scan was developed in the mid 1990s was voltage measured in relation to pain fiber function.
Many Neural-Scan studies have been published since it received FDA clearance. Each study adds support that the Neural-Scan is the Gold Standard in detecting pain fiber pathology.
Chronis Prostatitis Causing Pelvic Pain Due To Sacral Entrapment
Pain fiber NCS reveals lumbosacral nerve root lesions associated with prosatitis and pelvic pain syndromes. American College of Surgeons. October 10, 2008.
Neural-Scan Shows Correlation to VAS Scores
Alex Ambroz, MD Associate Clinical Professor John Marshall University Medical School
Neural-Scan Correlation to Abnormal Vertebral Motion
A Case Study, James L Hedgecock, PhD - AASM-ASEM 5th Annual Conference October 26-27, 2007 Newport Beach, California
Neural-Scan Analysis
Presented at the AASM-ASEM 5th Annual Conference October 26-27, 2007 Newport Beach, California
Predicting Nerve Root Pathology With Small Pain Fiber Nerve Conduction Studies (spf-NCS)
The Neural-Scan shows 95% sensitivity in detecting pre-DRG pathology
Nerve Conduction Sensory Testing
Summary: Nerve conduction sensory (NCS) test helps to diagnose severity, location & distribution of radiculopathy or neuropathy. Non-invasive method. Measures sensory threshold using neuroselective frequency to test Type A-delta fibers. Abnormally high NCS measures indicate significant nerve conduction loss. Abnormally low NCS indicate hyperesthetic state that corresponds with inflamed, irritated or regenerating nerves.
Neural-Scan Gets to the (Nerve) Root of Fibromyalgia
Summary: Using the Neural-Scan, LSU Pain Center found the majority of fibromyalgia patients have previously undiagnosed nerve-root pathology. Ten of these treated patients were available for a one-year follow-up. All ten were found free of all fibromyalgia symptoms.
Neural-Scan Helps Identify Piriformis Syndrome
Summary: This retrospective study of 50 patients found an 80% probability of concomitant piriformis syndrome when the Neural-Scan detected abnormal L5 and S1 dysfunction on the ipsilatyeral (same) side.
Neurosurgeon Reports: Neural-Scan Guided Lumbar Disc Decompression Therapy Improves Outcomes From 86% to 93%.
2005 - Presented: American Association of Sensory Medicine (ASSM) 3rd Annual Conference – October 2005 – San Francisco - Ronald Zellem, MD
In over 102 patients matching the criteria as surgical candidates the Neural-Scan was used to localize the exact level of herniation (pain fiber pathology) to guide decompression therapy. Instead of the usual 86% success rate reported in the literature, Dr. Zellem obtained 93% recoveries in these patients. This study is soon to be published.
Check the AASM web site www.sensorymedicine.org for more information.
|
|
|
|
|
|
|
|
|
Sole Distributor and Manufacturer: NDA, Inc. - Neural-ScanTM NCSs SystemTM
PHONE: 1-800-766-0884 - E-MAIL: email@nervepathology.com
Home | Learn More | Studies | News | Contact Us | Purchase
This website is not for general public use. It is meant for physician reference only.
Nothing presented is meant to represent or imply use other than the FDA Indication and usage.
FDA Indications and Usage: The Neural-ScanTM NCSs is a diagnostic device that allows the quantitative detection of various sensory neurological impairments caused by various pathological conditions or toxic substance exposures. The subject population for whom this device can be used for diagnostic purposes includes any individual capable of communicating the perception of cutaneous sensation (with the potentiometer, which has a separate FDA clearance, the test is not dependent on the subject reporting perception of the cutaneous sensation, since the action potential of the nerve firing is detectable by the potentiometer). The Neural-ScanTM NCSs diagnostic examination may be conducted as part the neurological examination or for screening to detect peripheral neuropathies.
Legal Notice
DOCUMENTS
Neuro-Diagnostic Associates (NDA), Incorporated. gives permission to use documents on this web site provided that:
- The NDA, Inc. copyright appears in copies and a permission notice appear, © 2007 NDA, Inc.
- Documents from this site are for informational and non-commercial or personal use only. Such will not be copied or posted to any network computer or broadcast or published in any media or method now or hereafter developed, and
- No modification of any document is made and no unauthorized purpose is prohibited by law. Violation may result in civil and/or criminal penalties.
Materials do not use the design or layout of the website.
INFORMATION ON NDA, INCORPORATED'S WEBSITE INCLUDING SPECIFICATIONS, APPEARANCE AND APPLICABILITY MAY BE SUBJECT TO CHANGE WITHOUT NOTICE. NO REPRESENTATIONS IS MADE OR IMPLIED AS TO THE SUITABILITY OF THE INFORMATION ON THIS SITE FOR ANY PURPOSE. THE FULL CONTENTS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND AND ARE SUBJECT TO CHANGE WITHOUT NOTICE. ANY TYPE OF RISK WHICH MAY ARISE OUT OF USE OF THIS INFORMATION REMAINS WITH THE RECIPIENT. IN NO EVENT SHALL NDA, INCORPORATED BE LIABLE FOR ANY DIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE OR OTHER DAMAGES (INCLUDING WITHOUT LIMITATION, DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION), EVEN IF NDA, INCORPORATED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
TRADEMARK NOTICE
All trademarks displayed on this website are subject to the U.S. trademark law, which support that any unauthorized use of trademarks is strictly prohibited.
Copyright © 2007 Neural-ScanTM NCSs SystemTM All Rights Reserved.
|
|
